BioSpace News Archive

Cassava Sciences, Inc today announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease.

Top researchers in the field of type 1 diabetes signed an open letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal Budget 2024.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology.

Aleve®, a marquee pain relief product from Bayer indicated for minor pain, in partnership with Mothers Against Prescription Drug Abuse, launched “The Painful Truth,” a campaign developed to encourage consumers to explore, with their doctors, pain relief options such as over-the-counter products before taking opioids, when appropriate.

Susan G. Komen®, the world’s leading breast cancer organization and Walgreens announced another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.

The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, and scientific director Dr. Andrew Leber for their leadership in the discovery and development of NX-13 that enabled today’s acquisition of Landos Biopharma, Inc. (“Landos”) by AbbVie, Inc. (NYSE: ABBV) (“AbbVie”).

Oxurion NV, a Leuven-based biopharmaceutical company, is pleased to announce its participation in the SmallCap event, scheduled for March 28 in Paris.

NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the Tau2024 Global Conference in Washington, D.C.

Praxis Precision Medicines, Inc. announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m. ET.

QIAGEN announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used QIAstat-Dx Analyzer 1.0 for reliable, fast and cost-effective diagnosis of complex syndromes.